Text Link
Text Link
Industry Dive's Dive D Icon
Industry Dive's Dive D Icon

State of Oncology Research

Recorded
Jun 5, 2025
Jun
, 
2025
2pm ET
Virtual event on-demand
Virtual event
Register for free

State of Oncology Research

Recorded
Jun 5, 2025
2pm ET
Virtual event
Register for free

Join the PharmaVoice and BioPharma Dive editorial teams for an exclusive event where our journalists will speak with top executives and experts to discuss the state of cancer drug research, its evolution and development.

This event will provide expert perspectives on the trends shaping oncology. Attendees will gain firsthand insights into the industry’s pipeline strategies, key takeaways from the American Society of Clinical Oncology’s annual meeting and the growing role of China-based drug developers.

What to expect:

  • One-on-one discussions with industry leaders spotlighting pipeline strategies for antibody-drug conjugates and immunotherapies
  • Expert panel discussions on the most consequential ASCO data and how it may shift cancer research and treatment
  • A panel discussion on the role of China-based drug companies and their influence in the field

Who should attend?

  • Executives and employees at oncology-focused companies
  • Cancer researchers and physicians, especially those following the 2025 ASCO meeting
  • Partners and associates at venture capital firms
  • Other professionals in the biopharma and healthcare space

Reserve Your Spot Today!

Register for free

Watch now











Success

Your seat has been reserved! Please check your email for a registration confirmation and more information on how to access the event.

Event powered by

No items found.

Agenda

This event will feature two fireside chats and two panels featuring Dive journalists and leading executives and experts from key companies in the oncology field. Topics covered will include antibody-drug conjugates, data from the 2025 ASCO meeting, emerging cancer drugs and more. Specific times for each session to be announced soon.

Sessions

Session 1 Building a blockbuster ADC franchise This in-depth conversation on the competitive field of antibody-drug conjugates will explore how Daiichi Sankyo built one of the industry’s leading ADC franchises, and examine what its future holds. Session 2 Panel A wide-ranging discussion on the most consequential data coming from this year’s ASCO meeting, and how it might shape cancer research and treatment. Session 3 Panel A discussion on the pipeline of cancer drugs emerging from laboratories and companies in China, and how oncology-focused companies in the U.S. and Europe are responding. Session 4 The future of cancer care & next phase of Merck’s oncology portfolio Merck & Co.’s immunotherapy Keytruda is the highest-selling oncology drug of all time, but patents protecting it are due to expire in the coming years. This fireside chat will dig into Merck’s development strategy and what comes next for the company.

Questions

If you have questions about registration, if you’re interested in speaking, or have any other questions, contact us at [email protected].

Speakers

Dr. Marjorie Catherine Green // Senior Vice President and Head, Global Oncology Clinical Development // Merck & Co.
Ken Keller // CEO, President, Board Chair, Head of Global Oncology // Daiichi Sankyo Inc.
Jonathan Gardner // Senior Reporter // BioPharma Dive
Michael Gibney // Senior Editor & Writer // PharmaVoice
Ned Pagliarulo // Lead Editor // BioPharma Dive
Meagan Parrish // Lead Editor // PharmaVoice

About our newsroom

BioPharma Dive and PharmaVoice provide in-depth journalism and insight into the most impactful news and trends shaping their industries, covering topics such as biotech, pharma, drug development, R&D, and more.

BioPharma Dive and PharmaVoice are leading publications operated by Informa TechTarget. Our business journalists spark ideas and shape agendas for 16 million decision makers in 20+ competitive industries.